Search | Clinical Trials Finder

Conditions: Oncology
Interventions: Sym013; Drug
Lead sponsor: Symphogen A/S; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 3
States / cities: Nashville, Tennessee • San Antonio, Texas

Conditions: Leptomeningeal Metastases
Interventions: Involved-field Photon Radiation Therapy, Proton Craniospinal Irradiation (CSI), Neurocognitive Assessment, MDASI-BT and MDASI-SP; Radiation · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: Up to 99 Years
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 7
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Edentulous Alveolar Ridge
Interventions: Gintuit, Bio-Gide; Biological · Device
Lead sponsor: Organogenesis; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Pancreas Cancer, Exosomes, Extracellular Vesicles, Pancreatic Neoplasms
Interventions: Not listed
Lead sponsor: Biological Dynamics; Industry
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: San Diego, California

Conditions: Stroke, Ischemic Stroke, Stroke in Middle Cerebral Artery (MCA)
Interventions: ALD-401, Sham Procedure; Biological · Procedure
Lead sponsor: Aldagen; Industry
Eligibility: 30 Years to 83 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 9
States / cities: Los Angeles, California • Miami, Florida • Minneapolis, Minnesota + 6 more

Conditions: Pancreatic Cancer
Interventions: PEGPH20, Cetuximab, DW & DCE-MRI, blood draws; Drug · Device · Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Leukemia
Interventions: Heavy Water (2H2O), PCI-32765; Other · Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Advanced Solid Tumors
Interventions: ginisortamab, trifluridine/tipiracil, mFOLFOX6; Drug
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 3
States / cities: Los Angeles, California • Charleston, South Carolina • Houston, Texas

Conditions: Metastatic Castration Resistant Prostate Cancer
Interventions: Pembrolizumab; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 13
States / cities: San Francisco, California • West Los Angeles, California • Washington D.C., District of Columbia + 10 more

Conditions: Child Behavior Problems
Interventions: Immediate CARE; Behavioral
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 2 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Depressive Disorder, Major
Interventions: Brenipatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 36
States / cities: Birmingham, Alabama • Phoenix, Arizona • Irvine, California + 28 more

Conditions: Ovarian Cancer, Primary Peritoneal Cancer, Serous Carcinoma Cancer, Triple-Negative Breast Cancer, Fallopian Tube Cancer
Interventions: ABT-888, Cyclophosphamide; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 124 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 9
States / cities: Davis, California • Tampa, Florida • Chicago, Illinois + 6 more

Conditions: Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic
Interventions: upifitamab rilsodotin; Drug
Lead sponsor: Mersana Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Cervical Priming
Interventions: misoprostol, placebo; Drug
Lead sponsor: Ferring Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years · Female only
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 2
States / cities: Phoenix, Arizona • Winston-Salem, North Carolina

Conditions: Bladder Cancer, URINARY BLADDER
Interventions: gemcitabine and cisplatin plus sorafenib; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Multimorbidity
Interventions: SLIMM - Sit less, interact, move more, PB125; Behavioral · Dietary Supplement
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 60 Years and older
Enrollment: 120 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Cognitive Flexibility, Emotional Regulation
Interventions: Healthy Minds Program, Sham Meditation Didactic Material, Sham Stimulation in Lab, Stimulation in Lab, MRI Scanner; Other · Device
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 50 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Lymphoid Leukemia, Acute, Myeloid Malignancy, Plasma Cell Tumor
Interventions: T-cell Receptor α/β Depleted Donor Lymphocyte Infusions; Biological
Lead sponsor: Guenther Koehne; Other
Eligibility: 18 Years to 74 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Metastatic Head-and-neck Squamous-cell Carcinoma, Unresectable Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
Interventions: Time restricted eating (TRE); Behavioral
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: COVID-19
Interventions: Azeliragon, Placebo; Drug
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 3
States / cities: Chicago, Illinois • Ann Arbor, Michigan • Galveston, Texas

Conditions: Huntington's Disease
Interventions: Not listed
Lead sponsor: University College, London; Other
Eligibility: 11 Years to 75 Years
Enrollment: 2,500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2017
U.S. locations: 6
States / cities: Englewood, Colorado • Washington D.C., District of Columbia • Baltimore, Maryland + 3 more

Conditions: Polycystic Kidney, Autosomal Dominant
Interventions: Tesevatinib; Drug
Lead sponsor: Kadmon, a Sanofi Company; Industry
Eligibility: 18 Years to 62 Years
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 11
States / cities: Los Angeles, California • Denver, Colorado • Kansas City, Kansas + 8 more

Conditions: Amyloid Plaque, Beta-Amyloid, DSAD, Prodromal Alzheimer's Disease, Alzheimer's Disease
Interventions: Placebo (Study Part 1a), ACI-24.060 at Dose A in Study Part 1a, ACI-24.060 at Dose B in Study Part 1a, ACI-24.060 at Dose C in Study Part 1a, ACI-24.060 with an additional adjuvant at Dose D in Study Part 1b, Placebo (Study Part 2), ACI-24.060 at Dose A in Study Part 2, ACI-24.060 at Dose B in Study Part 2, ACI-24.060 at Dose C in Study Part 2, Placebo (Study Part 1b), ACI-24.060 with an additional adjuvant at Dose E in Study Part 1b; Biological
Lead sponsor: AC Immune SA; Industry
Eligibility: 35 Years to 85 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2029
U.S. locations: 13
States / cities: Phoenix, Arizona • Lady Lake, Florida • Orlando, Florida + 9 more

Conditions: Left Ventricular Systolic Dysfunction, Heart Failure (Pediatric)
Interventions: Finerenone (Kerendia, BAY94-8862); Drug
Lead sponsor: Bayer; Industry
Eligibility: Up to 18 Years
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 22
States / cities: Aurora, Colorado • Wilmington, Delaware • Gainesville, Florida + 18 more

Search by objective public record fields.

Sym013 (Pan-HER) in Patients With Advanced Epithelial Malignancies

Proton Craniospinal Radiation Therapy vs. Partial Photon Radiation Therapy for Leptomeningeal Metastasis From Solid Tumors

Safety Study of Gintuit™ in Subjects Requiring Socket Grafting

ExoLuminate Study for Early Detection of Pancreatic Cancer

Study of ALD-401 Via Intracarotid Infusion in Ischemic Stroke Subjects

Two Stage Study Of Single Dose PEGPH20 And Cetuximab In Patients With Pancreatic Adenocarcinoma Prior To Surgical Resection

Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL

A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors

A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation

Parent Program to Improve Child Behavior Problems

A Study of Brenipatide (LY3537031) in Adult Participants With Major Depressive Disorder

Phase II ABT-888 With Cyclophosphamide

First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b

Efficacy and Safety Study of the Misoprostol Vaginal Priming Insert (MVPI) Prior to Hysteroscopy

Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naïve Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Physical Activity Modifies Exercise Responsiveness

The STRENGTHEN Study

T-cell Receptor α/β Depleted Donor Lymphocyte Infusion

Time Restricted Eating (TRE) in Metastatic Head and Neck Squamous Cell Cancer (mHNSCC) or Unresectable or Metastatic Renal Cell Carcinoma (RCC)

A Randomized, Double-Blind, Placebo-Controlled Phase 2/3 Study to Determine the Safety and Effectiveness of Azeliragon in the Treatment of Patients Hospitalized for Coronavirus Disease 2019 (COVID-19) or Pneumonia

HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease

A Safety, Pharmacokinetic & Dose-Escalation Study of KD019 in Subjects With Autosomal Dominant Polycystic Kidney Disease

A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)

A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Children and Young Adults With Heart Failure and Left Ventricular Systolic Dysfunction